Abstract |
In a therapy-resistant epileptic population with partial complex seizures with or without secondary generalization, addition of flunarizine to existing therapy was accompanied by a significant reduction in complex partial and tonic-clonic seizures. This result did not appear to be due to serial effects or changes in the plasma levels of the co-medication. Side effects were rare. The serum flunarizine levels (13.8 ng/ml; range, 3-32.5 ng/ml) were lower than previously reported on a daily dose of 10 mg. This may reflect increased metabolism due to induction of liver enzymes by the co-medication. Given this finding, together with the low incidence of side effects, a further study is required to determine whether higher blood levels would give an improved degree and incidence of seizure reduction.
|
Authors | J Overweg, C D Binnie, J W Meijer, H Meinardi, S T Nuijten, S Schmaltz, A Wauquier |
Journal | Epilepsia
(Epilepsia)
Vol. 25
Issue 2
Pg. 217-22
(Apr 1984)
ISSN: 0013-9580 [Print] United States |
PMID | 6705752
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Piperazines
- Vasodilator Agents
- Cinnarizine
- Flunarizine
|
Topics |
- Adolescent
- Adult
- Cinnarizine
(adverse effects, analogs & derivatives, therapeutic use)
- Drug Therapy, Combination
- Epilepsy
(drug therapy)
- Female
- Flunarizine
- Humans
- Male
- Middle Aged
- Piperazines
(therapeutic use)
- Vasodilator Agents
(therapeutic use)
|